Gene expression profiling in follicular lymphoma and its implication for clinical practice

Leukemia and Lymphoma

Volumn 52, Issue 1, 2011, Pages 59-68

  Janikova, Andrea ^a   Tichy, Boris ^a   Supikova, Jana ^a   Stano Kozubik, Katerina ^a   Pospisilova, Sarka ^a   Kren, Leos ^a   Vasova, Ingrid ^a   Salek, David ^a   Mayer, Jiri ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Follicular lymphoma; gene expression profiling; lymphomagenesis; prognosis

Indexed keywords

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER RELAPSE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL PRACTICE; FOLLICULAR LYMPHOMA; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC ANALYSIS; HUMAN; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE;

ADULT; AGED; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, FOLLICULAR; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 78651300740     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.531412     Document Type: Article

References (48)

1. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of hemopoie-tic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
2. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20(Suppl. 5):75-88.
3. Lister TA. Improved survival for patients with follicular lymphoma. J Clin Oncol 2005;23:4830-4831.
4. Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006;24:1582-1589.
5. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005; 23:5019-5026.
6. Tan D, Rosenberg SA, Levy R, et al. Survival in follicular lymphoma: the Stanford experience, 1960-2003. Blood 2007;110(Suppl. 1):Abstract 3428.
7. Conconi A, Motta M, Bertoni F, et al. Patterns of survival of follicular lymphomas at a single institution through three decades. Leuk Lymphoma 2010;51:1028-1034.
8. Lossos I., Levy R. Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. Semin Cancer Biol 2003;13:191-202.
9. Nathwani BN, Harris NL, Weisenburger DD. Follicular lymphoma. In: Jaffe ES, Harris NL, Stein H, et al., editors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp 162-167.
10. Klapper W, Hoster E, Rolver L, et al. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. J Clin Oncol 2007;25:3330-3306.
11. Koster A, Tromp HA, Raemaekers JM, et al. The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma. Haematologica 2007;92:184-190.
12. A clinical evaluation of the International Lymphoma Study Group of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918.
13. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104: 1258-1265.
14. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate-or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006;108:1504-1508.
15. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
16. Glas AM, Kersten MJ, Delahaye LJ, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105:301-307.
17. Davies AJ, Rosenwald A, Wright G, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol 2007;136:286-293.
18. Harjunpää A, Taskinen M, Nykter M, et al. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Br J Haematol 2006; 135:33-42.
19. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351: 2159-2169.
20. Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007;25:390-398.
21. Bohen SP, Troyanskaya OG, Alter O, et al. Variation of gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci USA 2003;100:1926-1930.
22. Goy A, Stewart J, Barkoh BA, et al. The feasibility of gene expression profiling generated in fine-needle aspiration specimens from patients with follicular lymphoma and diffuse large B-cell lymphoma. Cancer 2006;108:10-20.
23. Janikova A, Mayer J, Kren L, et al. The persistence of t(14;18)-bearing cells in lymph nodes of follicular lymphoma patients in complete remission: the evidence of 'a lymphoma stem cell'? Leuk Lymphoma 2009;50:1102-1109.
24. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
25. Dave SS, Fu K, Wright GW, et al. Lymphoma/Leukemia Molecular Profiling Project: molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006;354:2431-2442.
26. Hummel M, Bentink S, Berger H, et al. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe: a biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006;354:2419-2430.
27. Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003;102:2951-2959. (Pubitemid 37248870)
28. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1:133-143.
29. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
30. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. Bio-techniques 2003;34:374-378.
31. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003;4:R70.
32. Pavlidis P, Noble WS. Analysis of strain and regional variation in gene expression in mouse brain. Genome Biol 2001;2:RE-SEARCH0042.
33. Björck E, Landgren O, Jerkeman M, et al. High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood 2005;105:2908-2915.
34. Rimsza LM, Leblanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffin-embedded tissue of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008; 112:3425-3433.
35. Pusztai L, Ayers M, Stec J, et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumours. Clin Cancer Res 2003;9:2306-2415.
36. Schmechel SC, LeVasseur RJ, Yang KH, Koehler KM, Kussick SJ, Sabath DE. Identification of genes whose expression patterns differ in benign lymphoid tissue and follicular, mantle cell, and small lymphocytic lymphoma. Leukemia 2004;18:841-855.
37. Fujii A, Oshima K, Hamasaki M, et al. Differential expression of cytokines, chemokines and their receptors in follicular lympho-ma and reactive follicular hyperplasia: assessment by complementary DNA microarray. Oncol Rep 2005;13:819-824.
38. Fan X, Lobenhofer EK, Chen M, et al. Consistency of predictive signature genes and classifiers generated using different microarray platforms. Pharmacogenomics J 2010;10: 247-257.
39. Tibshirani R. Immune signatures in follicular lymphoma. N Engl J Med 2005;352:1496-1497; author reply 1496-1497.
40. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macro-phage (LAM) content is an independent predictor survival in follicular lymphoma (FL). Blood 2005;106:2169-2174.
41. Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T-cells is associated with improved overall survival in follicular lympho-ma. Blood 2006;108:2957-2964.
42. Lee AM, Clear AJ, Calaminici M, et al. Number of CD4 cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006;24:5052-5059.
43. Wahlin BE, Sander B, Christensson B, Kimby E. CD8 T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007;13:388-397.
44. Martinez-Climent JA, Alizadeh AA, Segraves R, et al. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with heterogeneous set of DNA copy number and gene expression alterations. Blood 2003;101:3109-3117.
45. De Vos S, Hofmann WK, Grogan TM, et al. Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest 2003;83:271-285.
46. Ruminy P, Jardin F, Piquenot JM, et al. Sm mutation patterns suggest different progression pathways in follicular lymphoma: early direct or late from FL progenitor-cells. Blood 2008; 112:1951-1959.
47. de Jong D, Koster A, Hagenbeek A, et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 2009;94:70-77.
48. Elenitoba-Johnson KS, Jenson SD, Abbott RT, et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci USA 2003;100:7259-7264.